FDA Proposes Electronic Registration for All Manufacturers and Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Proposes Electronic Registration for All Manufacturers and Drugs
A new system would enhance enforcement, promote access to drug information, and help identify illegal drug manufacturing.


Pharmaceutical Technology


This language outlining the pharmacy exemption reflects the continuing debate over FDA's authority to regulate large-scale compounders as drug manufacturers. Compounding pharmacists, who are regulated by state law, traditionally produce liquid versions of solid oral-dosage forms for children and patients who cannot swallow pills. They also formulate custom medicines for patients who are allergic to certain excipients and dyes found in commercial products. To avoid being considered drug manufacturers, pharmacists perform such compounding in response to legal prescriptions for specific patients. Some drug formulation may be done in anticipation of receiving a certain number of prescriptions, but not in large volumes for sale through third parties or via Internet Web sites.

FDA, pharmacists, Congress, and the courts have struggled for years over just where to draw the line between legitimate compounding and large-scale operations that qualify as drug manufacturing. FDA wants large compounders to register and comply with GMPs and other requirements to ensure product quality. Growing concerns about drug safety and counterfeiting have generated support for tighter controls, particularly for sterile products to treat serious health conditions. An emerging fear is that compounders open the door for counterfeit active pharmaceutical ingredients (APIs) to enter the US market.

The scope of compounding is unclear. An FDA study in 2001 estimated that some 650 pharmacies fill more than 13 million prescriptions for compounded products each year. But this may be a minimum: FDA officials frequently cite estimates of 30 million compounded prescriptions. Another measure of compounding might be the number of specific problems linked to compounded products. Between 1990 and 2003, FDA says it identified more than 55 product-quality problems associated with compounded drugs, many resulting in recalls.

New warnings

In the past, FDA has challenged compounding in various product categories, including hormonal products, veterinary drugs, steroids, and injectibles. Last year, FDA sent a warning letter to a veterinary compounding facility in Nebraska for large-scale compounding of drugs for resale by third parties. Manufacturers and patient groups have petitioned FDA to take action against compounders. Last year, Wyeth filed a citizens' petition seeking restrictions on the compounding of hormonal therapies identical to its "Premarin."

The latest skirmish involves home health agencies' distribution of large volumes of compounded sterile liquids used in nebulizers by patients with asthma and other respiratory diseases. FDA sent a warning letter in August 2006 instructing CCS Medical (Clearwater, FL, http://www.ccsmed.com/) to halt large-scale production of albuterol and other respiratory medications. A similar letter cites Rotech Healthcare (Orlando, FL, http://www.rotech.com/) for failing to comply with GMPs in producing budesonide and albuterol inhalation products. Another letter to Lincare's Reliant Pharmacy Services (Clearwater, FL, http://www.lincare.com/) reiterated concerns raised in a warning letter issued in December 2004.

In announcing this compliance action, Steven Galson, director of the Center for Drug Evaluation and Research (CDER), noted that using unapproved inhalation drugs that are not produced according to GMPs and "typically are not sterile" may "expose patients to unnecessary risk." Rotech said that even though it disagreed with FDA's findings, it would stop accepting prescriptions for inhalation products and begin the process of shifting some 30,000 patients to commercially available treatments.

Charges that home healthcare companies are substituting compounded products for prescription nebulizer medications prompted Senate Finance Committee Chairman Charles Grassley (R-IA) to launch a probe of these activities last March. The investigators found the use of unregistered below-grade bulk chemicals, and Astra Zeneca and other pharmaceutical manufacturers provided Grassley's staffers with independent tests of compounded drug samples indicating different concentrations, failed sterility tests, and bacterial contamination that could cause infections in people with weakened immune systems. In response to Grassley's report, the Centers for Medicare and Medicaid Services (CMS) said it would revise its coding system to reduce Medicare payments for inhalant drugs produced by compounders, as opposed to products from registered manufacturers.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here